Pharsight

Verquvo generic

Verquvo is an anti-heart failure drug owned by Merck Sharp Dohme. The drug contains the active ingredient vericiguat and was first authorized for market use on 19 January, 2021.

When will Verquvo generic be available?

Verquvo generic is expected to be available after 26 November, 2032, when the patent US9604948 titled 'Process for preparing substituted 5-fluoro-1H-pyrazolopyridines', expires. Drug patent challenges can be filed against Verquvo starting from 19 January, 2025.

Verquvo uses

Verquvo is used to reduce the risk of cardiovascular death and heart failure hospitalization. It is particularly beneficial for adults with symptomatic chronic heart failure and ejection fraction less than 45%. The active ingredient, vericiguat, contributes to the drug's effectiveness.

Verquvo patent expiration

Verquvo holds a total of 6 drug patents, none of which have expired. The last patent to expire is US9604948, titled 'Process for preparing substituted 5-fluoro-1H-pyrazolopyridines', with an expiry date of 26 November, 2032, potentially marking the release date for Verquvo generic. Below are the details of the patent:

Verquvo dosage

Want to ask something?